 Connection
Holly Lindsay to Adolescent
This is a "connection" page, showing publications Holly Lindsay has written about Adolescent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.261 |
|
|
|
-
Lindsay HB, Scheurer ME, Allam AK, Lucas BJ, McGovern SL, Chintagumpala M, Paulino AC. Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
Score: 0.053
-
Lindsay H, Gruner S, Brackett J. Cefepime-Induced Neurotoxicity Despite Dose Adjustment for Renal Disease: A Brief Report and Review of the Literature. J Pediatric Infect Dis Soc. 2017 Jun 01; 6(2):199-201.
Score: 0.033
-
Lindsay H, Huang Y, Du Y, Braun FK, Teo WY, Kogiso M, Qi L, Zhang H, Zhao S, Mao H, Lin F, Baxter P, Su JM, Terashima K, Perlaky L, Chintagumpala M, Adesina A, Lau CC, Williams Parsons D, Li XN. Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
Score: 0.030
-
Smith AA, Onar-Thomas A, Lensing S, Dalton J, Bennett J, Tatevossian RG, Bertrand K, Lindsay H, Tabori U, Owens-Pickle E, Blackburn PR, Handler MH, Chambwe N, El Khoury L, Lau C, Kunin-Batson A, Sands S, Wu S, Zhou T, Chang A, Merchant TE, Leary S, Fouladi M, Gajjar A, Pollack IF, Foreman NK, Ellison DW. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group. Neuro Oncol. 2026 May 01; 28(5):1286-1297.
Score: 0.015
-
Aguilar SL, Reddy K, Schneider NM, Whittle SB, Foster JH, Lindsay HB, Gruner S, Parmeter M, Fatih OM. A Quality Improvement Initiative: Increasing Awareness of Long-Term Follow-Up Care in Pediatric Cancer Survivors and Caregivers. J Pediatr Hematol Oncol. 2026 Mar 01; 48(2):e84-e90.
Score: 0.015
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
Score: 0.015
-
Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S. Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
Score: 0.014
-
Abu-Arja MH, Brown AL, Su JM, Okcu MF, Lindsay HB, McGovern SL, McAleer MF, Grosshans DR, Chintagumpala MM, Paulino AC. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.014
-
Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 08 10; 42(23):2769-2779.
Score: 0.013
-
Daignault C, Sauer HE, Lindsay H, Alonzo A, Foster J. Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
Score: 0.011
-
Serrallach BL, Tran BH, Bauer DF, Mohila CA, Adesina AM, McGovern SL, Lindsay HB, Huisman TA. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report. Neuroradiol J. 2022 Oct; 35(5):634-639.
Score: 0.011
-
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA, Su JM, Xiao S, Erickson SW, Earley EJ, Teicher B, Smith MA, Li XN. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
Score: 0.011
-
Mohiuddin S, Maraka S, Usman Baig M, Gupta S, Muzzafar T, Valyi-Nagy T, Lindsay H, Moody K, Razvi S, Paulino A, Slavin K, Gondi V, McCutcheon I, Zaky W, Khatua S. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review. J Clin Neurosci. 2021 Jul; 89:405-411.
Score: 0.011
-
Liu ZG, Jiang G, Tang J, Wang H, Feng G, Chen F, Tu Z, Liu G, Zhao Y, Peng MJ, He ZW, Chen XY, Lindsay H, Xia YF, Li XN. c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma. Oncotarget. 2016 Oct 04; 7(40):65946-65956.
Score: 0.008
-
Zhao X, Zhao YJ, Lin Q, Yu L, Liu Z, Lindsay H, Kogiso M, Rao P, Li XN, Lu X. Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors. Neuro Oncol. 2015 Jul; 17(7):965-77.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|